Osteotropic Therapy via Targeted Layer-by-Layer Nanoparticles
Name
Hammond_Osteotropic therapy.pdf
Size
2.28 MB
Format
Adobe PDF
Checksum (MD5)
c056ce56790006d9345a218ed6b26f3a
Author(s)
Morton, Stephen Winford
Shah, Nisarg J.
Deng, Zhou J.
Poon, Zhiyong
Quadir, Mohiuddin Abdul
Hammond, Paula T
Date Issued
June 2014
Journal
Advanced Healthcare Materials
Publisher
Wiley-VCH Verlag GmbH & Co.
Citation
Morton, Stephen W., Nisarg J. Shah, Mohiuddin A. Quadir, Zhou J. Deng, Zhiyong Poon, and Paula T. Hammond. “Osteotropic Therapy via Targeted Layer-by-Layer Nanoparticles.” Advanced Healthcare Materials 3, no. 6 (October 9, 2013): 867–875.
Version
Author's final manuscript
Abstract
Current treatment options for debilitating bone diseases such as osteosarcoma, osteoporosis, and bone metastatic cancer are suboptimal and have low efficacy. New treatment options for these pathologies require targeted therapy that maximizes exposure to the diseased tissue and minimizes off-target side effects. This work investigates an approach for generating functional and targeted drug carriers specifically for treating primary osteosarcoma, a disease in which recurrence is common and the cure rate has remained around 20%. This approach utilizes the modularity of Layer-by-Layer (LbL) assembly to generate tissue-specific drug carriers for systemic administration. This is accomplished via surface modification of drug-loaded nanoparticles with an aqueous polyelectrolyte, poly(acrylic acid) (PAA), side-chain functionalized with alendronate, a potent clinically used bisphosphonate. Nanoparticles coated with PAA-alendronate are observed to bind and internalize rapidly in human osteosarcoma 143B cells. Encapsulation of doxorubicin, a front-line chemotherapeutic, in an LbL-targeted liposome demonstrates potent toxicity in vitro. Active targeting of 143B xenografts in NCR nude mice with the LbL-targeted doxorubicin liposomes promotes enhanced, prolonged tumor accumulation and significantly improved efficacy. This report represents a tunable approach towards the synthesis of drug carriers, in which LbL enables surface modification of nanoparticles for tissue-specific targeting and treatment.
MIT Department
Massachusetts Institute of Technology. Institute for Soldier Nanotechnologies
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1002/adhm.201300465
